Bioventus director corrects 9,000 RSU grant record

Cowdy Philip G. reported acquisition or exercise transactions in this Form 4 filing.

Rhea-AI Filing Summary

Cowdy Philip G. reported acquisition or exercise transactions in this Form 4 filing.

Bioventus Inc. director Philip G. Cowdy filed an amended insider report to correct a previously reported equity grant. A prior Form 4 had shown a grant of 9,000 restricted stock units, but the footnote explains this grant was not accepted. As of February 11, 2021, he held no non-derivative or derivative securities of Bioventus.

Insider Trade Summary

Grant/Award: 9,000 shares

Grant/Award 1 txn

Insider Cowdy Philip G.

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Restricted Stock Units	9,000	$0.00	$0.00

Holdings After Transaction: Restricted Stock Units — 0 contracts (Direct)

Footnotes (2)

1. F1. On February 16, 2021, the Issuer inadvertently filed a Form 4 reporting a grant of restricted stock units that were not accepted by the Reporting Person. As of February 11, 2021, the Reporting Person held no non-derivative or derivative securities of the Issuer.
2. F2. None.

Key Figures

RSU grant referenced: 9,000 restricted stock units Holdings after correction: 0 securities Grant price per unit: $0.0000 per unit

3 metrics

RSU grant referenced 9,000 restricted stock units Previously reported grant later stated as not accepted

Holdings after correction 0 securities Non-derivative and derivative holdings as of February 11, 2021

Grant price per unit $0.0000 per unit Reported price for the referenced restricted stock unit grant

Key Terms

Restricted Stock Units, Form 4, non-derivative, derivative securities

4 terms

Restricted Stock Units financial

"the Issuer inadvertently filed a Form 4 reporting a grant of restricted stock units"

Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.

Form 4 regulatory

"the Issuer inadvertently filed a Form 4 reporting a grant"

Form 4 is a official document that company insiders, such as executives or major shareholders, file with regulators whenever they buy or sell company shares. It provides transparency about how those with inside knowledge are trading, helping investors see if insiders are confident in the company's prospects or may be selling for personal reasons. This information can influence investor decisions by revealing insiders' perspectives on the company's value.

non-derivative financial

"held no non-derivative or derivative securities of the Issuer"

derivative securities financial

"held no non-derivative or derivative securities of the Issuer"

Financial contracts whose value is tied to the price or performance of another asset, such as a stock, bond, commodity, index, or currency; examples include options, futures and swaps. They matter to investors because they let you protect against price swings, bet on future moves or gain larger exposure with less upfront cash—like using a lever or insurance policy on an investment—so they can amplify gains and losses and help manage portfolio risk.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What does the Bioventus (BVS) Form 4/A for Philip G. Cowdy report?

The Form 4/A shows an amended insider report for director Philip G. Cowdy. It corrects a previously filed Form 4 that had reported a grant of restricted stock units which, according to the footnote, was not actually accepted by the reporting person.

How many restricted stock units were involved in the Bioventus (BVS) amendment?

The amendment references a grant of 9,000 restricted stock units. The footnote clarifies that this grant, previously reported on an earlier Form 4, was not accepted, so it did not result in actual holdings for the reporting person.

Did Bioventus director Philip G. Cowdy hold any shares as of February 11, 2021?

According to the filing footnote, as of February 11, 2021, Philip G. Cowdy held no non-derivative or derivative securities of Bioventus Inc. This clarifies his position after correcting the previously misreported restricted stock unit grant.

What was incorrect in the earlier Bioventus (BVS) Form 4 for Philip G. Cowdy?

The earlier Form 4, filed on February 16, 2021, inadvertently reported a grant of 9,000 restricted stock units. The amendment states that these units were not accepted by the reporting person, so the original filing did not accurately reflect his holdings.

Does the Bioventus (BVS) Form 4/A show any insider buying or selling?

The Form 4/A centers on a reported grant of restricted stock units with zero price per unit. The footnote explains that this grant was not accepted, and the reporting person held no securities as of February 11, 2021, so no effective buying or selling occurred.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 04/14/2026 - 06:19 PM EDT Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Cowdy Philip G.

(Last) (First) (Middle)

4721 EMPEROR BOULEVARD, SUITE 100

(Street)

DURHAM NORTH CAROLINA 27703

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Bioventus Inc. [ BVS ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
02/11/2021

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)
02/16/2021

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Restricted Stock Units(1)	(2)	02/11/2021		A		9,000		(2)	(2)	Class A Common Stock	9,000	$0	0	D

Explanation of Responses:

1. On February 16, 2021, the Issuer inadvertently filed a Form 4 reporting a grant of restricted stock units that were not accepted by the Reporting Person. As of February 11, 2021, the Reporting Person held no non-derivative or derivative securities of the Issuer.

2. None.

Remarks:

	/s/ Anthony D'Adamio, Attorney-in-Fact	04/14/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)